Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis

• DOI: 10.1007/s13300-025-01704-z
• Publication Date: 2025-02-14T08:37:25Z
• Authors: Yoshiyuki Hamamoto; Tomonori Oura; Tetsuaki Hirase
• Keywords: BETA (programming language)

The objective of this work was to assess the association tirzepatide with changes in insulin sensitivity and beta-cell function Japanese patients type 2 diabetes (T2D). This a prespecified analysis SURPASS J-mono, multicenter, randomized, double-blind, active-controlled phase 3 study participants T2D. Participants were randomly assigned receive 5, 10, 15 mg, or dulaglutide 0.75 mg once weekly for 52 weeks. Changes from baseline homeostatic model assessment (HOMA2) parameters assessed by mixed repeated measures. Post hoc subgroup analyses conducted based on high low C-peptide categories (cutoff: median 1.86 µg/l). included 636 (tirzepatide 5 mg: n = 159; 10 158; 160; 159). Fasting levels significantly reduced at week all three doses compared (estimated treatment differences [ETDs] respectively: insulin, − 22.6%, 29.8%, 31.0%; C-peptide, 14.2%, 21.5%, 20.7%; p < 0.001 comparisons). Insulin indices increased groups 0.75-mg group (ETDs HOMA2-%S [insulin], 31.8%, 43.2%, 49.9%; [C-peptide], 24.8%, 33.9%, 38.2%; HOMA2-%B 27.3%, 34.9%, 40.6%; 31.6%, 40.1%, 46.7%; Regardless level, showed significant improvement glycated hemoglobin (C-peptide µg/l: 2.31% 2.75% vs. 1.45%; ≥ 2.43% 2.89% 1.12%; 0.001). In these post analyses, associated improved secretion T2D, which may result fasting levels. NCT03861052.